Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice.

Cancers (Basel) · 2022 · PMC9179270 · PMID 35681701

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

We were not able to document a significant influence of the first-line treatment in NET G3 patients on mOS, but there was a slight trend toward better survival with the use of STZ + FU (only used in pancreatic NET G3 patients) and temozolomide plus capecitabine as compared to platinum-containing combinations.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.